Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Psychiatry Neurosci. 2011 Mar;36(2):78-86. doi: 10.1503/jpn.100057.

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.

Author information

  • 1Mental Health Research Institute, Parkville, Victoria, Australia. oliviad@barwonhealth.org.au

Abstract

There is an expanding field of research investigating the benefits of alternatives to current pharmacological therapies in psychiatry. N-acetylcysteine (NAC) is emerging as a useful agent in the treatment of psychiatric disorders. Like many therapies, the clinical origins of NAC are far removed from its current use in psychiatry. Whereas the mechanisms of NAC are only beginning to be understood, it is likely that NAC is exerting benefits beyond being a precursor to the antioxidant, glutathione, modulating glutamatergic, neurotropic and inflammatory pathways. This review outlines the current literature regarding the use of NAC in disorders including addiction, compulsive and grooming disorders, schizophrenia and bipolar disorder. N-acetylcysteine has shown promising results in populations with these disorders, including those in whom treatment efficacy has previously been limited. The therapeutic potential of this acetylated amino acid is beginning to emerge in the field of psychiatric research.

PMID:
21118657
[PubMed - indexed for MEDLINE]
PMCID:
PMC3044191
Free PMC Article

Images from this publication.See all images (1)Free text

Fig. 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for The Canadian Medical Association Icon for PubMed Central
    Loading ...
    Write to the Help Desk